DE10002509A1 - Substituierte Glutarimide - Google Patents

Substituierte Glutarimide

Info

Publication number
DE10002509A1
DE10002509A1 DE10002509A DE10002509A DE10002509A1 DE 10002509 A1 DE10002509 A1 DE 10002509A1 DE 10002509 A DE10002509 A DE 10002509A DE 10002509 A DE10002509 A DE 10002509A DE 10002509 A1 DE10002509 A1 DE 10002509A1
Authority
DE
Germany
Prior art keywords
group
general formula
formula
alkyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE10002509A
Other languages
German (de)
English (en)
Inventor
Tieno Germann
Stefanie Frosch
Erik Wade
Helmut Buschmann
Oswald Zimmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Priority to DE10002509A priority Critical patent/DE10002509A1/de
Priority to MXPA02007089A priority patent/MXPA02007089A/es
Priority to AU25140/01A priority patent/AU780636B2/en
Priority to HU0204235A priority patent/HUP0204235A3/hu
Priority to KR1020027009243A priority patent/KR20020067614A/ko
Priority to DK01900400.1T priority patent/DK1252144T3/da
Priority to ES01900400T priority patent/ES2337875T3/es
Priority to PT01900400T priority patent/PT1252144E/pt
Priority to NZ520759A priority patent/NZ520759A/en
Priority to CNB018038883A priority patent/CN1185215C/zh
Priority to SI200130961T priority patent/SI1252144T1/sl
Priority to PL01356986A priority patent/PL356986A1/xx
Priority to IL15081301A priority patent/IL150813A0/xx
Priority to BR0108030-0A priority patent/BR0108030A/pt
Priority to SK1017-2002A priority patent/SK287173B6/sk
Priority to AT01900400T priority patent/ATE451355T1/de
Priority to JP2001553265A priority patent/JP2003524641A/ja
Priority to PCT/EP2001/000155 priority patent/WO2001053261A1/de
Priority to RU2002121641/04A priority patent/RU2278857C2/ru
Priority to DE50115252T priority patent/DE50115252D1/de
Priority to EP01900400A priority patent/EP1252144B1/de
Priority to CA002398061A priority patent/CA2398061A1/en
Priority to CO01003816A priority patent/CO5261626A1/es
Priority to ARP010100251A priority patent/AR030185A1/es
Priority to PE2001000061A priority patent/PE20011067A1/es
Publication of DE10002509A1 publication Critical patent/DE10002509A1/de
Priority to NO20023319A priority patent/NO323395B1/no
Priority to US10/198,073 priority patent/US6656937B2/en
Priority to ZA200206664A priority patent/ZA200206664B/en
Priority to US10/653,188 priority patent/US20040048859A1/en
Priority to CY20101100143T priority patent/CY1109784T1/el
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
DE10002509A 2000-01-21 2000-01-21 Substituierte Glutarimide Ceased DE10002509A1 (de)

Priority Applications (30)

Application Number Priority Date Filing Date Title
DE10002509A DE10002509A1 (de) 2000-01-21 2000-01-21 Substituierte Glutarimide
HU0204235A HUP0204235A3 (en) 2000-01-21 2001-01-09 Substituted glutarimides and use thereof il-12 production inhibitors, process for their preparation and pharmaceutical compositions containing them
PCT/EP2001/000155 WO2001053261A1 (de) 2000-01-21 2001-01-09 Substituierte glutarimide und ihre verwendung als inhibitoren der il-12 produktion
AT01900400T ATE451355T1 (de) 2000-01-21 2001-01-09 Substituierte glutarimide und ihre verwendung als inhibitoren der il-12 produktion
KR1020027009243A KR20020067614A (ko) 2000-01-21 2001-01-09 치환된 글루타르이미드 및 ｉｌ-12 생성 억제제로서의이의 용도
DK01900400.1T DK1252144T3 (da) 2000-01-21 2001-01-09 Substituerede glutarimider og deres anvendelse som inhibitorer af IL-12-produktionen
ES01900400T ES2337875T3 (es) 2000-01-21 2001-01-09 Glutarimidas sustituidas y utilizacion de las mismas como inhibidores de la produccion de il-12.
PT01900400T PT1252144E (pt) 2000-01-21 2001-01-09 Glutarimidas substituídas e sua utilização como inibidores da produção de il-12
NZ520759A NZ520759A (en) 2000-01-21 2001-01-09 Substituted glutarimides and use thereof IL-12 production inhibitors
CNB018038883A CN1185215C (zh) 2000-01-21 2001-01-09 取代的戊二酰亚胺及其作为il－12产生抑制剂的用途
SI200130961T SI1252144T1 (sl) 2000-01-21 2001-01-09 Substituirani glutarimidi in njihova uporaba kot inhibitorji proizvajanja IL-12
PL01356986A PL356986A1 (en) 2000-01-21 2001-01-09 Substituted glutarimides and use thereof il-12 production inhibitors
AU25140/01A AU780636B2 (en) 2000-01-21 2001-01-09 Substituted glutarimides and use thereof IL-12 production inhibitors
BR0108030-0A BR0108030A (pt) 2000-01-21 2001-01-09 Glutarimidas substituidas, e seu uso como inibidores de produção de il-12.
SK1017-2002A SK287173B6 (sk) 2000-01-21 2001-01-09 Substituované glutarimidy, spôsob ich výroby a ich použitie ako liečiv
MXPA02007089A MXPA02007089A (es) 2000-01-21 2001-01-09 Glutarimidas sustituidas y su uso como inhibidores de la produccion de il-12.
JP2001553265A JP2003524641A (ja) 2000-01-21 2001-01-09 置換されたグルタルイミド及びこれをｉｌ−１２産生阻害剤として使用する方法
IL15081301A IL150813A0 (en) 2000-01-21 2001-01-09 Substituted glutarimides and use thereof il-12 production inhibitors
RU2002121641/04A RU2278857C2 (ru) 2000-01-21 2001-01-09 Замещенные глутаримиды, способы получения и лекарственное средство на их основе
DE50115252T DE50115252D1 (de) 2000-01-21 2001-01-09 Substituierte glutarimide und ihre verwendung als inhibitoren der il-12 produktion
EP01900400A EP1252144B1 (de) 2000-01-21 2001-01-09 Substituierte glutarimide und ihre verwendung als inhibitoren der il-12 produktion
CA002398061A CA2398061A1 (en) 2000-01-21 2001-01-09 Substituted glutarimides and their use as inhibitors of il-12 production
ARP010100251A AR030185A1 (es) 2000-01-21 2001-01-19 Glutarimidas sustituidas, su preparacion, medicamentos que las contienen, y uso de las mismas para la fabricacion de medicamentos, especialmente inmunomoduladores, como asi tambien inhibidores de angiopatias y/o enfermedades hematologicas/oncologicas
CO01003816A CO5261626A1 (es) 2000-01-21 2001-01-19 Glutarimidas sustituidas, su preparacion, medicamentos que las contienen, y uso de las mismas para la fabricacion de medicamentos, especialemente inmunomoduladores, como asi tambien inhibidores de angiopatias y/o enfermedades hematologicas/oncologica
PE2001000061A PE20011067A1 (es) 2000-01-21 2001-01-19 Glutarimidas sustituidas, su preparacion, medicamentos que las contienen, y uso de las mismas para la fabricacion de medicamentos, especialmente inmunomoduladores, como asi tambien inhibidores de angiopatias y/o enfermedades hematologicas/oncologicas
NO20023319A NO323395B1 (no) 2000-01-21 2002-07-09 Substituerte glutarimider som er inhibitorer av IL-12-produksjonen, fremgangsmate for fremstilling derav, anvendelse derav samt legemidler inneholdende forbindelsene.
US10/198,073 US6656937B2 (en) 2000-01-21 2002-07-19 Substituted glutarimides and their use as inhibitors of IL-12 production
ZA200206664A ZA200206664B (en) 2000-01-21 2002-08-20 Substituted glutarimides and use thereof IL-12 production inhibitors.
US10/653,188 US20040048859A1 (en) 2000-01-21 2003-09-03 Substituted glutarimides and their use as inhibitors of IL-12 production
CY20101100143T CY1109784T1 (el) 2000-01-21 2010-02-11 Υποκατεστημενα γλουταριμιδια και η χρησιμοποιηση τους σαν αναστολεις της il-12 παραγωγης

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10002509A DE10002509A1 (de) 2000-01-21 2000-01-21 Substituierte Glutarimide

Publications (1)

Publication Number Publication Date
DE10002509A1 true DE10002509A1 (de) 2001-07-26

Family

ID=7628270

Family Applications (2)

Application Number Title Priority Date Filing Date
DE10002509A Ceased DE10002509A1 (de) 2000-01-21 2000-01-21 Substituierte Glutarimide
DE50115252T Expired - Lifetime DE50115252D1 (de) 2000-01-21 2001-01-09 Substituierte glutarimide und ihre verwendung als inhibitoren der il-12 produktion

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE50115252T Expired - Lifetime DE50115252D1 (de) 2000-01-21 2001-01-09 Substituierte glutarimide und ihre verwendung als inhibitoren der il-12 produktion

Country Status (28)

Country Link
US (2) US6656937B2 (es)
EP (1) EP1252144B1 (es)
JP (1) JP2003524641A (es)
KR (1) KR20020067614A (es)
CN (1) CN1185215C (es)
AR (1) AR030185A1 (es)
AT (1) ATE451355T1 (es)
AU (1) AU780636B2 (es)
BR (1) BR0108030A (es)
CA (1) CA2398061A1 (es)
CO (1) CO5261626A1 (es)
CY (1) CY1109784T1 (es)
DE (2) DE10002509A1 (es)
DK (1) DK1252144T3 (es)
ES (1) ES2337875T3 (es)
HU (1) HUP0204235A3 (es)
IL (1) IL150813A0 (es)
MX (1) MXPA02007089A (es)
NO (1) NO323395B1 (es)
NZ (1) NZ520759A (es)
PE (1) PE20011067A1 (es)
PL (1) PL356986A1 (es)
PT (1) PT1252144E (es)
RU (1) RU2278857C2 (es)
SI (1) SI1252144T1 (es)
SK (1) SK287173B6 (es)
WO (1) WO2001053261A1 (es)
ZA (1) ZA200206664B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053956A1 (de) * 2001-12-21 2003-07-03 Grünenthal GmbH In 3-position heterocyclisch substituierte piperidin-2,6-dione

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10002509A1 (de) * 2000-01-21 2001-07-26 Gruenenthal Gmbh Substituierte Glutarimide
US7842727B2 (en) 2001-03-27 2010-11-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
CA2486303C (en) 2002-05-22 2013-04-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on alpha-ketoepoxide compounds
AU2003243285A1 (en) * 2002-05-22 2003-12-12 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on trihalomethylcarbonyl compounds
US20040192738A1 (en) * 2003-03-18 2004-09-30 Aventis Pharma Deutschland Gmbh 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl] benzamide, its use as a medicament, and pharmaceutical preparations comprising it
ATE533745T1 (de) 2004-03-17 2011-12-15 Pfizer Prod Inc Neue benzyl(iden)-lactam-derivate
DE102004026703A1 (de) * 2004-05-28 2005-12-29 Grünenthal GmbH Verfahren zur Herstellung von in 3-Position heterocyclisch substituierten Piperidin-2,6-dionen
WO2014107622A1 (en) 2013-01-07 2014-07-10 University Of Southern California Deoxyuridine triphosphatase inhibitors
US9815814B2 (en) * 2013-04-12 2017-11-14 Obschestvo S Ogranichennoi Otvetstvennostiyu “Pharmenterprises” Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
JP6513095B2 (ja) 2014-01-03 2019-05-15 ユニバーシティ オブ サザン カリフォルニア ヘテロ原子含有デオキシウリジントリホスファターゼ阻害剤
US10577321B2 (en) 2015-07-08 2020-03-03 University Of Southern California Deoxyuridine triphosphatase inhibitors
WO2017006271A1 (en) 2015-07-08 2017-01-12 University Of Southern California Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage
US10544105B2 (en) 2015-07-08 2020-01-28 Cv6 Therapeutics (Ni) Limited Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage
EP3319939A1 (en) 2015-07-08 2018-05-16 CV6 Therapeutics (NI) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
RU2610275C2 (ru) * 2015-07-30 2017-02-08 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения
US11395820B2 (en) * 2016-03-16 2022-07-26 H. Lee Moffitt Cancer Center And Research Institute, Inc. Small molecules against cereblon to enhance effector t cell function
WO2018098206A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
US10829457B2 (en) 2016-11-23 2020-11-10 Cv6 Therapeutics (Ni) Limited Nitrogen ring linked deoxyuridine triphosphatase inhibitors
US11168059B2 (en) 2016-11-23 2021-11-09 Cv6 Therapeutics (Ni) Limited Amino sulfonyl compounds
WO2018098207A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
US11174271B2 (en) 2016-11-23 2021-11-16 Cv6 Therapeutics (Ni) Limited 6-membered uracil isosteres
US11247984B2 (en) 2017-01-05 2022-02-15 Cv6 Therapeutics (Ni) Limited Uracil containing compounds
EA201992341A8 (ru) * 2017-09-07 2020-08-11 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Применение производного глутаримида для лечения заболеваний, связанных с аберрантной активностью цитокинов
IL273432B (en) 2017-09-22 2022-09-01 Kymera Therapeutics Inc Protein compounds and their uses
EP3684366A4 (en) 2017-09-22 2021-09-08 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES OF THE LATEST
SG11202005912PA (en) 2017-12-26 2020-07-29 Kymera Therapeutics Inc Irak degraders and uses thereof
US11485743B2 (en) 2018-01-12 2022-11-01 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2019140387A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
CN107903245B (zh) * 2018-01-15 2018-11-13 青岛大学附属医院 一种化合物及其在制备治疗类风湿性关节炎药物中的应用
CN107857754B (zh) * 2018-01-15 2018-11-09 泰山医学院 一种化合物及其在制备预防/治疗类风湿性关节炎药物中的应用
WO2020010177A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
US11730726B2 (en) 2018-07-11 2023-08-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. Dimeric immuno-modulatory compounds against cereblon-based mechanisms
US11352350B2 (en) 2018-11-30 2022-06-07 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
MA55565A (fr) 2019-04-05 2022-02-09 Kymera Therapeutics Inc Agents de dégradation de stat et leurs utilisations
BR112022011651A2 (pt) 2019-12-17 2022-08-23 Kymera Therapeutics Inc Degradadores de irak e usos dos mesmos
EP4076524A4 (en) 2019-12-17 2023-11-29 Kymera Therapeutics, Inc. IRAQ DEGRADERS AND USES THEREOF
TW202136242A (zh) 2019-12-23 2021-10-01 美商凱麥拉醫療公司 Smarca降解劑及其用途
JP2023518423A (ja) 2020-03-19 2023-05-01 カイメラ セラピューティクス， インコーポレイテッド Ｍｄｍ２分解剤およびそれらの使用
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
BR112022026356A2 (pt) * 2020-06-26 2023-01-17 Valenta Intellekt Ltd Uso de um derivado de glutarimida para tratar doenças associadas à atividade aberrante da interleucina-6

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2673205A (en) * 1951-02-13 1954-03-23 Ciba Pharm Prod Inc 3-disubstituted dioxopiperidines and the manufacture thereof
US5300516A (en) * 1989-12-12 1994-04-05 Pfizer Inc. Muscarinic receptor antagonists
EP0856513A2 (de) * 1997-02-01 1998-08-05 Grünenthal GmbH Thalidomidanaloge Verbindungen aus der Klasse der Piperidin-2,6-Dione
US6008360A (en) * 1996-03-07 1999-12-28 Sanofi-Synthelabo Substituted 3-aryl-3-carboxyalkyl glutaramides, method for preparing same by 4-arylo-4-cyanoheptane dicarboxylic acid cyclisation, and use thereof for preparing 3-aryl-3-hydroxyalkylpiperidines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3214431A (en) * 1958-08-04 1965-10-26 Pfizer & Co C Novel glutarimides
US5114937A (en) * 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
DE19843793C2 (de) * 1998-09-24 2000-08-03 Gruenenthal Gmbh Substituierte Benzamide
DE10002509A1 (de) * 2000-01-21 2001-07-26 Gruenenthal Gmbh Substituierte Glutarimide

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2673205A (en) * 1951-02-13 1954-03-23 Ciba Pharm Prod Inc 3-disubstituted dioxopiperidines and the manufacture thereof
US5300516A (en) * 1989-12-12 1994-04-05 Pfizer Inc. Muscarinic receptor antagonists
US6008360A (en) * 1996-03-07 1999-12-28 Sanofi-Synthelabo Substituted 3-aryl-3-carboxyalkyl glutaramides, method for preparing same by 4-arylo-4-cyanoheptane dicarboxylic acid cyclisation, and use thereof for preparing 3-aryl-3-hydroxyalkylpiperidines
EP0856513A2 (de) * 1997-02-01 1998-08-05 Grünenthal GmbH Thalidomidanaloge Verbindungen aus der Klasse der Piperidin-2,6-Dione

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chemical Abstract, Vol.119, 1993, Ref. 49190b *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053956A1 (de) * 2001-12-21 2003-07-03 Grünenthal GmbH In 3-position heterocyclisch substituierte piperidin-2,6-dione
US7183274B2 (en) 2001-12-21 2007-02-27 Gruenenthal Gmbh Piperidine-2,6-diones heterocyclically substituted in the 3-position

Also Published As

Publication number Publication date
AU780636B2 (en) 2005-04-07
CN1185215C (zh) 2005-01-19
RU2002121641A (ru) 2004-01-10
BR0108030A (pt) 2003-01-28
ZA200206664B (en) 2004-01-21
NO20023319L (no) 2002-09-03
PT1252144E (pt) 2010-02-03
MXPA02007089A (es) 2002-12-13
AR030185A1 (es) 2003-08-13
CO5261626A1 (es) 2003-03-31
PL356986A1 (en) 2004-07-12
KR20020067614A (ko) 2002-08-22
EP1252144A1 (de) 2002-10-30
DK1252144T3 (da) 2010-04-19
PE20011067A1 (es) 2001-12-29
DE50115252D1 (de) 2010-01-21
SI1252144T1 (sl) 2010-04-30
US20030064987A1 (en) 2003-04-03
CY1109784T1 (el) 2014-09-10
AU2514001A (en) 2001-07-31
SK287173B6 (sk) 2010-02-08
IL150813A0 (en) 2003-02-12
CN1394201A (zh) 2003-01-29
CA2398061A1 (en) 2001-07-26
HUP0204235A3 (en) 2005-03-29
NO20023319D0 (no) 2002-07-09
EP1252144B1 (de) 2009-12-09
ES2337875T3 (es) 2010-04-30
HUP0204235A2 (hu) 2003-03-28
US6656937B2 (en) 2003-12-02
US20040048859A1 (en) 2004-03-11
ATE451355T1 (de) 2009-12-15
WO2001053261A1 (de) 2001-07-26
JP2003524641A (ja) 2003-08-19
NZ520759A (en) 2005-09-30
SK10172002A3 (sk) 2003-02-04
NO323395B1 (no) 2007-04-23
RU2278857C2 (ru) 2006-06-27

Similar Documents

Publication Publication Date Title
DE10002509A1 (de) Substituierte Glutarimide
DE19843793C2 (de) Substituierte Benzamide
DE69733135T2 (de) Substituierte imidazole mit cytokinin-inhibirender wirkung
DE69433501T2 (de) Oxazole zur behandlung von zytokinvermittelten erkrankungen
DE60018037T2 (de) Substituierte 2-aryl-3-(heteroaryl)-imidazo[1,2-alpha]pyrimidine und ihren verwandten arzneimittel und verfahren
DE60319158T2 (de) Pyrazoloisochinolinenderivaten als kinase inhibitoren
DE60214428T2 (de) 1, 4-dihydro-1, 4-diphenylpyridin-derivate
DE69926665T2 (de) Azolo-Pyrimidine
DE1770447A1 (de) In 1-Stellung substituierte 1,4-Dihydro-6,7-methylendioxy-4-oxo-chinolin-3-carbonsaeure-Derivate
DE3215269A1 (de) Durch eine heterocyklisch-aromatische gruppe n-substituierte, neuartige piperidin-, piperazin- und homopiperazin-derivate, ihr herstellungsverfahren und ihre anwendung in der therapie
DE2341965C3 (de) 4- [N- (o-PyridyD- N-acyl] -aminolphenäthylpiperidine, Verfahren zu deren Herstellung sowie deren Verwendung bei der Bekämpfung von Schmerzzuständen
DE602004005960T2 (de) Heteroaryl-substituierte pyrrolä2, 3- büpyridin-derivate als crf-rezeptor-antagonisten
EP0688771A1 (de) Verwendung von Lactamverbindungen als pharmazeutische Wirkstoffe
DE69824195T2 (de) Dipyridoimidazolderivate zur behandlung von störungen des zentralen nervensystems
EP1992349B1 (de) CGRP-antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1663993B1 (de) Guanidinderivate
EP0508370B1 (de) Kondensierte Diazepinone, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Mittel zur Behandlung von Erkrankungen des Zentralnervensystems und zur Förderung der cerebralen Durchblutung
DE69909592T2 (de) Verwendung von thiadiazolo[4,3-a]pyridine derivaten
DE2161827A1 (de) l-(3-Cyano-3,3-diphenylpropyl-)4phenylpiperidinderivate und Verfahren zu ihrer Herstellung
DE2832309C2 (es)
DE60004362T2 (de) Thiazolopyrimidine verwendbar als TNF-Alpha Inhibitoren
EP1456197B1 (de) In 3-position heterocyclisch substituierte piperidin-2,6-dione
DE19637043A1 (de) Neue Aminoalkoholderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel und Reagenzien
EP0190563A1 (de) Neue 12-Amino-pyridazino[4',5':3,4]pyrrolo-[2,1-a]isochinoline, Verfahren zu ihrer Herstellung und ihre Verwendung
CH645896A5 (de) Ergolinderivate.

Legal Events

Date Code Title Description
OM8 Search report available as to paragraph 43 lit. 1 sentence 1 patent law
8110 Request for examination paragraph 44
8131 Rejection